We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
- Authors
Rivero-Juárez, Antonio; Mira, José A.; Pérez-Camacho, Inés; Macías, Juan; Camacho, Angela; Neukam, Karin; Torre-Cisneros, Julián; Merchante, Nicolás; Pineda, Juan A.; Rivero, Antonio
- Abstract
Objectives The aim of this study was to evaluate whether the assessment of hepatitis C virus (HCV) RNA serum at 12 weeks after the end of treatment (W12) was as informative as after 24 weeks (W24) for determining sustained virological response (SVR) in HIV/HCV co-infected patients who received a combination of pegylated interferon (PEG-INF) plus ribavirin (PEG-INF/RBV) and had a virological response at the end of treatment. Methods Treatment-naive HIV/HCV patients were included in this prospective study if they had completed a full course of therapy with PEG-INF/RBV, had an undetectable serum HCV RNA at the end of treatment and complied with the W12 and W24 schedule for determining HCV RNA. HCV RNA levels were measured using a quantitative PCR assay (detection limit = 15 IU/mL). Positive predictive value (PPV) was defined as the probability of an undetectable serum HCV RNA at W12 and W24 after the end of treatment. Results Of 186 patients treated during the study period, 104 (55.9%) were included in the study. At W24, 83 (79.8%) patients had an SVR and 21 (20.2%) had a virological relapse. At W12, HCV RNA was undetectable in 83 (79.8%) patients and all of these had SVR. Undetectable HCV RNA at W12 had a 100% PPV [95% confidence interval (CI) 96.5%–100%] for SVR. Conclusions Our results show that undetectable HCV RNA at W12 post-treatment has a high PPV for SVR. Testing for HCV RNA at this moment may therefore be considered an appropriate point in time for identifying SVR and relapse in HIV/HCV co-infected patients receiving treatment with PEG-INF/RBV.
- Subjects
INTERFERONS; RIBAVIRIN; HIV infections; HEPATITIS C virus; RNA
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2011, Vol 66, Issue 6, p1351
- ISSN
0305-7453
- Publication type
Article
- DOI
10.1093/jac/dkr091